Valuation: Morepen Laboratories Limited

Market Cap 65.1B 678M 598M 565M 513M 962M 971M 6.77B 2.61B 33.24B 2.55B 2.49B 107B P/E 2025
21.8x
P/E 2026 19.5x
Enterprise Value 66.63B 694M 612M 578M 525M 985M 994M 6.93B 2.67B 34.02B 2.61B 2.55B 109B EV / Sales 2025
1.45x
EV / Sales 2026 1.11x
Free-Float
57.31%
Yield 2025
0.42%
Yield 2026 0.59%
1 day-1.49%
1 week-2.90%
Current month+10.91%
1 month+11.85%
3 months+123.56%
6 months+228.81%
Current year+189.26%
1 week 115.95
Extreme 115.95
126.1
1 month 97
Extreme 97
126.9
Current year 33.44
Extreme 33.44
126.9
1 year 33.44
Extreme 33.44
126.9
3 years 31.31
Extreme 31.31
126.9
5 years 23.65
Extreme 23.65
126.9
10 years 7.21
Extreme 7.21
126.9
Manager TitleAgeSince
Chief Executive Officer 58 30/06/2026
Chief Executive Officer 62 31/01/1992
Director of Finance/CFO 59 02/04/2002
Director TitleAgeSince
Chairman 62 31/01/1992
Director/Board Member 58 12/08/2019
Director/Board Member - 21/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.49%-2.90%+143.09%+227.00% 688M
-0.01%+1.69%+63.50%+117.58% 1,056B
-1.61%-0.71%+48.89%+70.56% 655B
-1.12%-0.45%+19.35%+72.93% 471B
-1.72%-4.25%+37.79%+39.89% 342B
-0.40%+4.12%+22.89%+29.04% 277B
-0.51%-1.05%+12.98%+12.92% 257B
+1.32%+7.75%+55.19%+56.43% 226B
-0.61%+0.48%+34.95%+100.58% 189B
-0.24%-3.21%-27.79%-61.37% 170B
Average -0.64%+0.17%+41.08%+66.56% 364.36B
Weighted average by Cap. -0.63%+0.76%+39.87%+68.95%

Financials

2025 2026
Net sales 18.12B 189M 166M 157M 143M 268M 270M 1.88B 726M 9.25B 709M 693M 29.7B 18.06B 188M 166M 157M 142M 267M 269M 1.88B 724M 9.22B 706M 691M 29.6B
Net income 1.18B 12.3M 10.84M 10.25M 9.3M 17.45M 17.6M 123M 47.32M 603M 46.18M 45.17M 1.93B 949M 9.89M 8.71M 8.24M 7.47M 14.03M 14.15M 98.65M 38.04M 484M 37.12M 36.31M 1.56B
Net Debt -928K -9.67K -8.52K -8.06K -7.31K -13.72K -13.84K -96.49K -37.2K -474K -36.31K -35.51K -1.52M 1.54B 16.03M 14.12M 13.35M 12.11M 22.74M 22.94M 160M 61.66M 785M 60.17M 58.86M 2.52B
Logo Morepen Laboratories Limited
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Employees
1,919
Date Price Change Volume
29/09/26 ₹118.80 -1.49% 738,907
28/09/26 ₹120.60 +0.12% 1,421,271
25/09/26 ₹120.45 +3.26% 724,153
24/09/26 ₹116.65 -4.66% 792,678
23/09/26 ₹122.35 +2.86% 586,598
  1. Stock Market
  2. Stocks
  3. MOREPENLAB Stock